Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CTRV

ContraVir Pharmaceuticals (CTRV) Stock Price, News & Analysis

ContraVir Pharmaceuticals logo

About ContraVir Pharmaceuticals Stock (NASDAQ:CTRV)

Key Stats

Today's Range
$0.60
$0.68
50-Day Range
$2.53
$3.58
52-Week Range
$3.52
$91.00
Volume
18,905 shs
Average Volume
432,822 shs
Market Capitalization
$520,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.

Receive CTRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraVir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CTRV Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

CTRV Stock Analysis - Frequently Asked Questions

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) issued its quarterly earnings results on Friday, May, 13th. The biopharmaceutical company reported ($1.12) EPS for the quarter, topping analysts' consensus estimates of ($1.80) by $0.68.

Shares of ContraVir Pharmaceuticals reverse split before market open on Tuesday, May 29th 2018. The 1-8 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 28th 2018. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that ContraVir Pharmaceuticals investors own include Ayala Pharmaceuticals (ADXS), Alliqua Biomedical (ALQA), Synergy Pharmaceuticals (SGYP), LadRx (CYTR), Madrigal Pharmaceuticals (MDGL), Palatin Technologies (PTN) and Protalix BioTherapeutics (PLX).

Company Calendar

Last Earnings
5/13/2016
Today
11/04/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CTRV
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Net Income
$-9,450,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.80 per share

Miscellaneous

Free Float
N/A
Market Cap
$520,000.00
Optionable
Not Optionable
Beta
1.16
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:CTRV) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners